LRRC2

Across TCGA pan-cancer cohorts, LRRC2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRRC2 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LRRC2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRRC2 expression acts as an unfavorable survival marker.

HNSC, UCEC, and PRAD are the cancer types where LRRC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.122	0.680	.004	21	view →
UCEC	OS	Median	IV	0.282	0.604	.024	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	III,IV	0.058	0.648	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LRRC2–HNSC (DFS)

Open the HNSC breakdown →